Скачать или смотреть Pharmacology of Brodalumab (Kyntheum, Siliq); Mechanism of action, Uses, Effects, Pharmacokinetics

Brodalumab (Kyntheum, Siliq) is a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), making it an IL-17 inhibitor used for moderate-to-severe plaque psoriasis.

Pharmacology
Mechanism of Action: Brodalumab binds to IL-17RA, blocking IL-17 signaling and reducing inflammation.

Absorption: Administered subcutaneously, with peak levels reached in 2 to 3 days.

Metabolism: Cleared via proteolytic degradation.

Elimination: Slow clearance, with a half-life of ~10-20 days.

Clinical Uses
Plaque Psoriasis: Approved for moderate-to-severe cases in adults.

Investigated for Psoriatic Arthritis and Crohn’s Disease.

Adverse Effects
Suicidal ideation and behavior (boxed warning; monitor mental health closely).

Serious infections (risk of tuberculosis and fungal infections).

Exacerbation of Crohn’s disease (contraindicated in Crohn’s patients).

Avoid live vaccines during treatment

#Brodalumab